

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.- 66. (Cancelled).

67. (Currently amended) A composition of matter having the following formula:




wherein p is 1;



wherein L comprises a physiologically compatible linker moiety which links the PBM and [MS-MM] moieties;

wherein said IEM comprises a complex between:

- (1) a chelating agent selected from the group consisting of DTPA, DOTA, DTPA-BMA, and HP-DO3A, and
- (2) one or more paramagnetic metal ions (M) with atomic numbers 21-29, 42, 44, or 57-83;

wherein said -PBM moiety is selected from the group consisting of:





, wherein at least one aryl ring of said -PBM of each member of the group is substituted with said $-\text{[L]}-\text{[MS-MM]}_p$ moiety;

wherein R can be a linear or branched alkyl aliphatic group having from 1 to 5 carbons, an aryl group, or a cycloalkyl group;

wherein the wavy line signifies the attachment site for the IEM;

wherein said -PBM moiety is conjugated to said IEM via a covalent bond to a methylene carbon of said chelating agent of said IEM;

wherein said MS moiety comprises is an amide bond;

wherein said MM moiety is a peptide ~~comprising~~ consisting of two or more or three
~~positively charged~~ amino acids;
and pharmaceutically acceptable salts thereof.




68. (Currently amended) The composition of claim 67, wherein said MM moiety is a peptide
~~comprising~~ consisting of two or more Arg, Lys, or tm-Lys amino acids, or mixtures thereof.

69. – 70. (Cancelled).


71. (Currently amended) The composition of claim ~~68~~ 67, wherein said MM moiety is –Arg-
tmLys-tmLys.

72. (Currently amended) The composition of claim ~~68~~ 67, wherein said MM moiety is Ile-
Arg-Lys.

73. (Currently amended) The composition of claim ~~68~~ 67, wherein said chelating agent is
selected from the group consisting of:




and



wherein the wavy line signifies the attachment site for the -PBM-L-MS-MM moiety.

74. (Currently amended) The composition of claim 68 67, wherein said chelating agent is



wherein the wavy line signifies the attachment site for the -PBM-L-MS-MM moiety.

75. (Previously presented) The composition of claim 67, wherein said paramagnetic metal ion is selected from the group consisting of:

- (a) Gd (III),
- (b) Mn (II),
- (c) Fe (III),

- (d) Cu (II),
- (e) Cr (III), and
- (f) Eu (III).

76. (Previously presented) The composition of claim 75, wherein said paramagnetic metal ion is Gd(III).


77. (Previously presented) The composition of claim 67, wherein the pharmaceutically acceptable salt is an N-methyl-D-glucamine, calcium, or sodium salt.

78. (Previously presented) The composition of claim 77, wherein the pharmaceutically acceptable salt is a sodium salt.

79. – 80. (Cancelled).

81. (Currently amended) A composition of matter having the following structure formula:

~~IEM-PBM (MS-MM),~~



wherein said IEM comprises a complex between:

- (1) a chelating agent selected from the group consisting of DTPA, DOTA, DTPA-BMA, and HP-DO3A, and
- (2) one or more paramagnetic metal ions (M) with atomic numbers 21-29, 42, 44, or 57-83;

~~said composition having the structure:~~

wherein ~~at least~~ one aryl ring of said structure is substituted with said a L-[MS-MM]_p moiety, wherein p is one;

wherein X is CH₂, O, or NH;

wherein L comprises a physiologically compatible linker moiety which links said one substituted aryl ring with said -[MS-MM]_p moiety;

wherein said MS moiety ~~comprises~~ is an amide bond;

wherein said MM moiety is a peptide ~~comprising~~ consisting of two or more or three positively charged amino acids;

and pharmaceutically acceptable salts thereof.




82. (Currently amended) The composition of claim 81, wherein said MM moiety is a peptide comprising consisting of two ~~or more~~ Arg, Lys, or tm-Lys amino acids, or mixtures thereof.

83. – 84. (Cancelled).


85. (Currently amended) The composition of claim ~~82~~ 81, wherein said MM moiety is -Arg-tmLys-tmLys.

86. (Currently amended) The composition of claim ~~82~~ 81, wherein said MM moiety is Ile-Arg-Lys.

87. (Currently amended) The composition of claim 81, wherein said chelating agent is selected from the group consisting of:




and



~~wherein the wavy line signifies the attachment site for the PBM-MS-MM moiety.~~

88. (Currently amended) The composition of claim 87, wherein said chelating agent is



wherein the wavy line signifies the attachment site for the ~~PBM MS MM moiety~~.

89. (Previously presented) The composition of claim 81, wherein said paramagnetic metal ion is selected from the group consisting of:

- (a) Gd (III),
- (b) Mn (II),
- (c) Fe (III),
- (d) Cu (II),
- (e) Cr (III), and
- (f) Eu (III).

90. (Previously presented) The composition of claim 89, wherein said paramagnetic metal ion is Gd(III).


91. (Previously presented) The composition of claim 81, wherein the pharmaceutically acceptable salt is an N-methyl-D-glucamine, calcium, or sodium salt.

92. (Previously presented) The composition of claim 91, wherein said pharmaceutically acceptable salt is a sodium salt.


93. – 94. (Cancelled).

95. (Currently amended) A method for magnetic resonance imaging, said method comprising:

96. (Currently amended) ~~The A compound according to claim 81~~ having the structure of Prodrug Compound 2:



or Prodrug Compound 10:



as set forth in the specification.

97. (New) The composition of claim 67 or 81, wherein said L moiety is a peptoid linkage.

98. (New) The composition of claim 67 or 81, wherein said L moiety has the following structure:

